Clinical Trials Browser

Phase 2/3 × Active not recruiting × Cisplatin × Clear all

Urinary Bladder Neoplasms

NCT03952585 2026-04-13

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Phase 2/3 Active not recruiting

384 enrolled 22 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

NCT05063552 2026-04-13

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Phase 2/3 Active not recruiting

430 enrolled

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT02135042 2026-04-03

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Phase 2/3 Active not recruiting

685 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT04559139 2026-03-19

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

Phase 2/3 Active not recruiting

186 enrolled

Gastrointestinal

Gallbladder Neoplasms

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

1,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05800015 2026-01-22

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Active not recruiting

950 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06115499 2026-01-07

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Phase 2/3 Active not recruiting

10 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02066220 2025-12-04

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Phase 2/3 Active not recruiting

360 enrolled

CNS

Brain Neoplasms, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT02867865 2025-03-13

POLCAGB

Phase 2/3 Active not recruiting

124 enrolled

Gastrointestinal

Gallbladder Neoplasms

NCT01924819 2025-03-04

TOPGEAR

Phase 2/3 Active not recruiting

574 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2/3 Active not recruiting

503 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02221999 2023-08-29

SHPD002

Phase 2/3 Active not recruiting

250 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Clinical Trials

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

B-FAST

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

POLCAGB

TOPGEAR

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

SHPD002